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Background: Clear-cell renal cell carcinoma (ccRCC) is a heterogeneous disease with a 
different clinical behavior and response to targeted therapies. Differences in hypoxia-inducible 
factor (HIF) expression have been used to classify von Hippel–Lindau gene (VHL)-deficient 
ccRCC tumors. c-Myc may be driving proliferation in HIF-2α-expressing tumors in a growth 
factor-independent manner.
Objective: To explore the HIF-1α, HIF-2α and c-Myc baseline expression as potential 
predictors of sunitinib outcome as well as the effectiveness and safety with sunitinib in patients 
with metastatic ccRCC in routine clinical practice.
Methods: This was an observational and prospective study involving 10 Spanish hospitals. 
Formalin-fixed, paraffin-embedded primary tumor samples from metastatic ccRCC patients 
who received sunitinib as first-line treatment were analyzed. Association between biomarker 
expression and sunitinib treatment outcomes was evaluated. Kaplan–Meier method was applied 
to measure progression-free survival (PFS) and overall survival.
Results: Eighty-one patients were included: median PFS was 10.8 months (95% CI: 7.4–
13.5 months), median overall survival was 21.8 months (95% CI: 14.7–29.8 months) and objec-
tive response rate was 40.7%, with 7.4% of patients achieving a complete response. Molecular 
marker staining was performed in the 69 available tumor samples. Significant association with 
lower PFS was identified for double c-Myc/HIF-2α-positive staining tumors (median 4.3 vs 
11.5 months, hazard ratio =2.64, 95% CI: 1.03–6.80, P=0.036). A trend toward a lower PFS 
was found in positive c-Myc tumors (median 5.9 vs 10.9 months, P=0.263). HIF-1α and HIF-2α 
expression levels were not associated with clinical outcome.
Conclusion: These preliminary results suggest that predictive subgroups might be defined based 
on biomarkers such as c-Myc/HIF-2α. Further validation with more patients will be needed 
in order to confirm it. Outcomes with sunitinib in metastatic ccRCC in daily clinical practice 
resemble those obtained in clinical trials.
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Introduction
Clear-cell renal cell carcinoma (ccRCC) is the most common type of adult kidney 
cancer. Local recurrence or distant metastasis develops in up to 40% of the patients 
treated for localized tumors.1,2
Despite the solid molecular and genetic background of antiangiogenic therapy in 
renal cell carcinoma (RCC), predictive biomarkers of response have not been identi-
fied. A few studies that concentrated on the genomic biomarkers and their impact on 
anti-vascular endothelial growth factor (anti-VEGF) targeted therapies have been 
reported.3–5 New tools are needed to identify the most suitable drug for an individual 
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patient; they are especially important nowadays due to the 
availability of new drugs for the treatment of RCC.6,7
Mutation or silencing of the von Hippel–Lindau gene 
(VHL) occurs in nearly 80% of sporadic ccRCC tumors.8–10 
Through its oxygen-dependent polyubiquitylation of 
hypoxia-inducible factors (HIFs), the VHL tumor suppres-
sor protein (pVHL) plays a central role in the mammalian 
oxygen-sensing pathway.11 In the absence of pVHL, HIF 
subunits (HIF-1α and HIF-2α) are stabilized, translocate to 
the nucleus, dimerize with the stable β-subunit (ARNT) and 
promote the expression of their target genes12 such as vascu-
lar endothelial growth factor (VEGF) and platelet-derived 
growth factor (PDGF). HIF-1α and HIF-2α have overlap-
ping effects on angiogenesis, invasion and metabolism, all of 
which contribute to tumor growth and progression, but each 
isoform also has unique targets.13 HIF-1α uniquely activates 
glycolytic enzyme genes, while HIF-2α preferentially acti-
vates transforming growth factor-α and Oct4 and promotes 
c-Myc transcriptional activity.14,15
In spite of the tremendous correlation of ccRCC with loss 
or inactivation of VHL, the effect on HIF deregulation is not 
uniform.16 Differences in HIF expression have been used to 
classify VHL-deficient ccRCC tumors into two subtypes, 
with one subtype expressing both HIF-1α and HIF-2α and 
another expressing only HIF-2α.13,17 These data show that 
ccRCC is a heterogeneous disease with a different clinical 
behavior and a different response to available targeted 
therapies.13,17
Sunitinib malate is a highly potent, selective inhibitor 
of certain protein tyrosine kinases including PDGFR-α 
and PDGFR-β; VEGF-1, VEGF-2 and VEGF-3; stem cell 
factor KIT receptor and FLT3.18–20 It is a standard of care for 
first-line treatment of metastatic ccRCC.21,22
Currently, predictive biomarkers for response to sunitinib 
are still lacking. This study assesses the value of HIF-1α, 
HIF-2α and c-Myc as potential molecular predictors of 
benefit from sunitinib as first-line treatment for metastatic 
ccRCC as well as the effectiveness outcomes in routine 
clinical practice.
Materials and methods
This is an observational and prospective study involving 
10 Spanish hospitals. Enrolled patients had a centralized 
pathologically confirmed diagnosis of metastatic RCC with 
a component of clear cell histology and received sunitinib 
as first-line treatment. Effectiveness data were prospectively 
assessed and retrospectively correlated with the expression 
of biomarkers of primary tumor samples.
All patients provided their written informed consent for 
this study. In accordance with the Spanish recommenda-
tions, the study was approved by the Ethics Committee of 
Santa Creu i Sant Pau Hospital, Central of Asturias Hospital 
(HUCA), Reina Sofía Hospital, Althaia Xarxa Asistencial 
de Manresa Hospital, Virgen del Rocio Hospital, Fundation 
Miguel Servet Hospital, Universitary Clinic of Navarra 
and Clinico Universitario de Santiago Hospital, and it was 
conducted in compliance with the principles contained in the 
Declaration of Helsinki.
Tumor response was monitored according to normal 
clinical practice and assessed according to Response Evalu-
ation Criteria in Solid Tumors.23 Tumor assessments were 
done as per local standard pattern of care for metastatic RCC. 
Safety and tolerability were assessed throughout treatment. 
Adverse events (AEs) were rated according to the National 
Cancer Institute for Adverse Events version 3.0 (NCI CTCAE 
v3.0.) and version 4.0 once it became available.
Sunitinib was administered orally at 50 mg/day (4 weeks 
on/2 weeks off). Drug reductions and drug interruptions 
were under label. Treatment continued until disease progres-
sion, unacceptable toxicity or withdrawal of consent.
immunohistochemistry
Tumor samples were available for 69 out of 81 patients. 
Formalin-fixed, paraffin-embedded primary tumor tissue 
samples were analyzed in the molecular analysis. Hema-
toxylin and eosin-stained sections of each tumor sample 
were examined by an experienced pathologist to confirm 
the diagnosis and to select the representative areas of pre-
served clear-cell histology. Two tissue microarrays with 
two to six tissue cores per tumor were constructed. Immu-
nohistochemistry (IHC) was performed on 4–5 µm tissue 
microarray sections. Antibodies were applied to sections at 
1:8000 dilution for HIF-1α (Cell Signaling), 1:500 dilution 
for HIF-2α (Nous Biologicals) and 1:300 dilution for c-Myc 
(DD Biosciences). Assays were conducted following the 
manufacturers’ instructions.
Molecular assessments of selected biomarkers were 
performed at the Pathology Laboratory of the Puigvert 
Foundation (Barcelona, Spain). C-Myc and HIF staining were 
assessed in the nucleus. IHC staining was considered positive 
in all cases with strong reactivity in any proportion $1%, 
except in the case of isolated cells.
Human placenta and thyroid gland were used as posi-
tive controls and tumor stroma as negative control. Staining 
was evaluated by an expert pathologist in the field, who was 
blinded to clinical information.
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statistical analysis
Median progression-free survival (PFS) and overall survival 
(OS) were estimated by the Kaplan–Meier method and sur-
vival distribution functions compared with the log-rank test. 
Objective response rate (ORR) was defined as the number 
of complete responses (CRs) or partial responses (PRs), and 
clinical benefit rate (CBR) was defined as the percentage 
of patients with advanced or metastatic cancer who have 
achieved CR, PR and stable disease. Patients were grouped 
according to the prognostic risk category on the basis of 
the Memorial Sloan-Kettering Cancer Center (MSKCC)24 
criteria: favorable (0 risk factors), intermediate (1–2 risk 
factors) and poor ($3 risk factors). The Heng classifica-
tion was not universally applied at the time the study was 
designed. Association between biomarkers’ expression and 
sunitinib treatment outcomes was evaluated. Tests were two-
tailed with a significance level of 5%. Data were analyzed 
using SPSS statistical software v17.0 (SPSS Inc., Chicago, 
IL, USA).
Results
A total of 81 patients with metastatic ccRCC were included 
from February 2008 to December 2010. Seventy-four tumors 
presented clear-cell histology and seven presented mixed 
histology with a clear-cell component. Table 1 summarizes 
the patient characteristics. The majority were men (66.7%) 
who had undergone prior nephrectomy (83.9%) and had an 
intermediate–poor prognostic risk according to MSKCC 
criteria (70.3%). Thirteen (16.0%) patients had an Eastern 
Cooperative Oncology Group performance status of $2. 
Lung was the most common site of metastasis (77.8%) and 
4.9% of the patients presented brain metastases (Table 1). 
Forty-nine (60.5%) of the patients presented a time interval 
of ,1 year between diagnosis and treatment.
Nonsignificant differences regarding baseline character-
istics were found between positive and negative biomarker 
groups (Tables 2 and 3) with the exception of differences in 
the metastatic patient rate at diagnosis in the nuclear Myc/
HIF-2α-positive group and the group of patients with at 
least Myc or HIF-2α-positive (80.0% vs 27.7%, P=0.0312; 
Table 3).
Efficacy and safety in the overall 
population
At a median follow-up of 32.4 months (95% CI: 28.2–38.4), 
the median PFS for all patients was 10.8 months (95% CI: 7.4–
13.5), as shown in Figure 1A. Seventy-two out of 81 patients 
reported were evaluable for PFS according to the MKSCC 
risk criteria. MSKCC risk group was not reported for nine 
patients. Median PFS for favorable, intermediate and poor 
risk groups was 11.5 months (95% IC: 6.0–not reached [NR]), 
10.8 months (95% CI: 6.7–17.8) and 8.6 months (95% CI: 
0.6–10.9), respectively (P=0.1131); also, poor risk vs favor-
able: hazard ratio (HR) 2.64 (1.02, 6.79) and intermediate risk 
vs favorable: HR 1.36 (0.68, 2.75), as shown in Figure 1B.
At the time of analyses, 50 (61.7%) patients had died. 
Median OS was 21.8 months (95% CI: 14.7–29.8). Median 
OS for favorable, intermediate and poor risk groups 
according to MKSCC criteria was 33.4 months (95% IC: 
18–NR), 21.8 months (95% CI: 13.8–35) and 10.7 months 
(95% CI: 0.6–21.6), respectively (P=0.010); also, poor risk 
vs favorable: HR 4.48 (1.58, 12.64) and intermediate risk vs 
favorable: HR 2.01 (0.83, 4.84).
Seventy-four (91%) patients were evaluable for tumor 
response; 6 (7.4%) patients achieved a CR, 27 (33.3%) a PR 
and 37 (45.6%) a stable disease (72.9% lasting .6 months 
and 56.7% lasting .9 months), yielding an ORR of 40.7% 
(29.9%, 52.2%) and a CBR of 86.4% (77.0%, 93.0%). 
Table 1 Baseline demographic and clinical characteristics
Characteristics Total (N=81)
Median age (Q1–Q3), years 60 (52–69)
Male, n (%) 54 (66.7)
Prior nephrectomy, n (%) 68 (83.9)
Metastatic at diagnosis, n (%) 28 (34.6)
stage, n (%)
iii 4 (4.9)
iV 71 (87.6)
ecOg Ps, n (%)
0 6 (7.4)
1 62 (76.5)
$2 13 (16.0)
MsKcc risk group, n (%)
Favorable (0 risk factor) 15 (18.5)
intermediate (1–2 risk factors) 47 (58.0)
Poor ($3 risk factors) 10 (12.3)
number of metastatic sites, n (%)
1 29 (35.8)
2 23 (28.4)
$3 29 (35.7)
site of metastases, n (%)
lung 63 (77.8)
lymph nodes 32 (39.5)
Bone 19 (23.5)
liver 14 (17.3)
Brain 4 (4.9)
Notes: Data are expressed as n (%). Missing data: MsKcc (n=9). risk factors are 
low serum hemoglobin level, elevated corrected serum calcium level, elevated serum 
lactate dehydrogenase level, a poor performance status (ecOg $2 or Karnosfky 
.80%) and an interval of ,1 year between diagnosis and treatment.
Abbreviations: ecOg Ps, eastern cooperative Oncology group performance 
status; MsKcc, Memorial sloan-Kettering cancer center.
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Table 4 shows the baseline characteristics of patients 
with CR.
The median duration of sunitinib treatment was 
10.5 months (Q1–Q3: 5.8–21.4). At the time of analysis, 68 
(83.9%) patients had discontinued treatment, 45 (66.1%) of 
them due to progressive disease, 12 (17.6%) due to AEs and 
4 (5.8%) due to both. Forty-eight (59.2%) patients needed 
dose reduction at least once. Toxicity was the main reason 
for dose reduction (87.5%). All patients were treated with 
the classical schedule 4 weeks on and 2 weeks off, and dose 
reductions were performed according to label.
Seventy-eight (96.3%) of the total patients experienced at 
least one treatment-related AE of any severity grade. Overall, 
most common related AEs were asthenia/fatigue (70.3%), 
mucosal inflammation (61.7%), hypertension (48.1%) and 
diarrhea (45.6%), neutropenia (37.0%), thrombocytopenia 
(32.10%), hand–foot syndrome (30.8%) and hypothyroid-
ism (29.6%). Grade 3 AEs most frequently occurring were 
asthenia/fatigue (22.2%), diarrhea (8.6%) and hand–foot 
syndrome (8.6%). Only one case of grade 4 toxicity (mucosal 
inflammation) was reported.
Molecular markers and clinical outcomes
Molecular marker staining was performed in the 69 avail-
able tumor samples with clear cell histology. Of the evalu-
able tumor samples, 29% (20/62) showed positive staining 
for HIF-1α, 29% (20/60) for HIF-2α, and 28% (19/60) for 
nuclear c-Myc, and 8% (5/60) showed double-positive stain-
ing for c-Myc and HIF-2α proteins (Figure 2).
Numerical but not statistically significant differences 
were observed regarding the PFS curves between patients 
bearing tumors with positive or negative c-Myc stain-
ing (5.9 vs 10.9 months, HR =1.44, 95% CI: 0.76–2.72, 
P=0.263) or between favorable/intermediate MSKCC risk 
patients with positive or negative c-Myc staining (5.9 vs 
12.7 months, HR =2.64, 95% CI: 1.03–6.80, P=0.1280), 
as shown in Figure 3. Significant association with lower 
PFS was identified for double c-Myc/HIF-2α-positive 
staining (4.3 vs 11.5 months) in tumors with at least 
one negative biomarker (HR =2.64, 95% CI: 1.03–6.80, 
P=0.0360), as shown in Figure 3. With regard to HIF-1α 
and HIF-2α, no statistically significant differences 
were found in PFS (median HIF-2α-positive staining 
8.5 months vs HIF-2α-negative staining 11.6, HR =1.6, 
P=0.05; median HIF-1α-positive staining 8.8 months 
vs HIF-1α-negative staining 11.5, HR =1.32, P.0.05). 
A similar trend in terms of OS was found in patients with 
positive staining compared with those with negative tumors 
for these biomarkers (median OS: c-Myc-positive staining 
Table 2 Baseline characteristics by c-Myc expression
Characteristics Negative 
c-Myc (n=41)
Positive 
c-Myc (n=19)
P-value
Metastatic at diagnosis 11 (26.8) 19 (31.6) 0.2367
Prior nephrectomy, n (%) 36 (87.8) 19 (100) 0.1684
ecOg Ps, n (%)
0 3 (7.4) 1 (5.3) 1.000
1 32 (78.1) 16 (84.2)
$2 6 (14.7) 2 (10.5)
MsKcc risk group, n (%)
Favorable (0 risk factor) 10 (24.4) 2 (10.5) 0.3474
intermediate (1–2 risk 
factors)
21 (51.2) 14 (73.7)
Poor ($3 risk factors) 6 (14.6) 2 (10.5)
not evaluable 4 (9.8) 1 (5.3)
number of metastatic sites, n (%)
1 14 (34.2) 20 (33.3) 0.7688
2 11 (26.8) 16 (26.7)
$3 16 (39.0) 24 (40.0)
site of metastases, n (%)
lung 35 (85.3) 14 (73.6) 0.3007
Bone 9 (21.9) 4 (21.0) 1.000
liver 6 (14.6) 4 (21.0) 0.7111
Brain 3 (7.3) 1 (5.2) 1.0000
Notes: Data are expressed as n (%). Missing data: MsKcc (n=9). risk factors are 
low serum hemoglobin level, elevated corrected serum calcium level, elevated serum 
lactate dehydrogenase level, a poor performance status (ecOg $2 or Karnosfky 
.80%) and an interval of ,1 year between diagnosis and treatment.
Abbreviations: ecOg Ps, eastern cooperative Oncology group performance 
status; MsKcc, Memorial sloan-Kettering cancer center.
Table 3 Baseline characteristics by c-Myc expression and hiF-2α
Characteristics Negative 
c-Myc or  
HIF-2α (n=55)
Positive 
c-Myc and 
HIF-2α (n=5)
P-value
Metastatic at diagnosis 15 (27.3) 4 (80.0) 0.0312
Prior nephrectomy, n (%) 50 (90.9) 5 (100) 1.0000
ecOg Ps, n (%)
0 3 (5.5) 1 (20.0) 0.2946
1 45 (81.8) 3 (60.0)
$2 7 (12.7) 1 (20.0)
MsKcc risk group, n (%)
Favorable (0 risk factor) 12 (21.8) 0 (0.0) 0.1531
intermediate (1–2 risk 
factors)
32 (58.2) 3 (60.0)
Poor ($3 risk factors) 6 (10.9) 2 (40.0)
not evaluable 5 (9.1) 0 (0.0)
number of metastatic sites, n (%)
1 17 (30.9) 3 (60.0) 0.5486
2 16 (29.19 0 (0.0)
$3 22 (40.01) 2 (40.0)
site of metastases, n (%)
lung 45 (81.8) 4 (80.0) 1.0000
Bone 11 (20.0) 2 (40.0) 0.2946
liver 9 (16.4) 1 (20.0) 1.0000
Brain 4 (7.3) 0 (0.0) 1.0000
Notes: Data are expressed as n (%). Missing data: MsKcc (n=9). risk factors are 
low serum hemoglobin level, elevated corrected serum calcium level, elevated serum 
lactate dehydrogenase level, a poor performance status (ecOg $2 or Karnosfky 
.80%) and an interval of ,1 year between diagnosis and treatment.
Abbreviations: ecOg Ps, eastern cooperative Oncology group performance 
status; hiF, hypoxia-inducible factor; MsKcc, Memorial sloan-Kettering cancer 
center.
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15.4 vs 24.1 months in negative tumors, HR =1.13, P.0.05; 
HIF-2α/c-Myc-positive staining 13.3 vs 24.1 months in 
tumors with at least one negative marker, HR =1.63, P.0.05; 
HIF-2α-positive staining 13.9 vs 32.8 months in negative 
tumors, HR =1.77, P.0.05; HIF-1α-positive staining 15 vs 
29.5 months in negative tumors, HR =1.80, P.0.05).
Discussion
In this study, primary tumors with double c-Myc/HIF-2α-
positive staining were associated with a significantly worst 
response to sunitinib in patients with mRCC. Meanwhile, 
analyses from only one biomarker related to HIF pathway 
have not shown it to be a predictor of response.
The Myc pathway is activated in most cases of human 
RCC,25 genomically amplified in 5%–10% of patients, over-
expressed in 20%10 and associated with a hereditary RCC 
syndrome.26,27 Vindrieux et al demonstrated that in RCC, loss 
of VHL tumor suppressor and activation of the oncogenic 
HIF-2α–c-MYC pathway repress the phospholipase A2 
receptor (PLA2R1) expression, which favors RCC tumori-
genicity.28 Recently, a study carried out with a conditional 
transgenic mouse model showed that c-Myc initiates and 
maintains RCC.29
HIF-1α and HIF-2α influence tumor progression by 
directly regulating unique and shared target genes. However, 
recent evidence indicates that these HIF-α proteins also affect 
tumor progression by exerting distinct, often opposing effects 
on critical oncogenes and tumor suppressors, including 
cMyc, p53 and mTOR.15 Particularly, the presence of HIF-1α 
directly blocks interaction of c-Myc with its DNA-binding 
partners, whereas HIF-2α might promote c-Myc interaction 
with Max and, thus, Sp1 and Miz1, by recruiting it directly 
to these complexes or by stabilizing these complexes once 
they are formed.14
A molecular classification of ccRCC based on the combi-
nation of VHL genotype and HIF-α expression, which could 
differentiate tumors responding to different targeted therapies 
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Figure 1 Kaplan–Meier estimates.
Notes: all patients PFs (A) and PFs according to MsKcc risk (B).
Abbreviations: MsKcc, Memorial sloan-Kettering cancer center; na, not applicable; PFs, progression-free survival.
Table 4 Baseline characteristics of patients with complete 
remission
Characteristics Total (n=6)
Median age (sD), years 50.2 (9.6)
Metastatic at diagnosis, n (%) 2 (33.3)
stage, n (%)
iii 1 (16.7)
iV 5 (83.3)
ecOg Ps, n (%)
0 2 (33.3)
1 4 (66.6)
MsKcc risk group, n (%)
Favorable (0 risk factor) 1 (16.7)
intermediate (1–2 risk factors) 3 (50.0)
not evaluable 2 (33.3)
number of metastatic sites, n (%)
1 3 (50.0)
2 2 (33.3)
$3 1 (16.7)
site of metastases, n (%)
lung 6 (100)
lymph nodes 3 (50.0)
Bone 0 (0.0)
liver 0 (0.0)
Brain 0 (0.0)
Kidney 1 (16.7)
Notes: Data are expressed as n (%). Missing data: MsKcc (n=9). risk factors are 
low serum hemoglobin level, elevated corrected serum calcium level, elevated serum 
lactate dehydrogenase level, a poor performance status (ecOg $2 or Karnosfky 
.80%) and an interval of ,1 year between diagnosis and treatment.
Abbreviations: ecOg Ps, eastern cooperative Oncology group performance 
status; MsKcc, Memorial sloan-Kettering cancer center.
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Figure 2 examples of immunohistochemistry.
Notes: (A) c-Myc-positive staining; (B) c-Myc-negative staining; (C) hiF-1α-positive staining; (D) hiF-1α-negative staining; (E) hiF-2α-negative staining; (F) hiF-2α-positive 
staining. Magnification (A and E) 400×; (B, C, D and F) 100×.
Abbreviation: hiF, hypoxia-inducible factor.
(mTOR inhibitors vs tyrosine kinase inhibitors), has been 
proposed.13 Wild-type VHL tumors, as well as VHL-deficient 
tumors expressing detectable HIF-1α and HIF-2α proteins, 
exhibit enhanced Akt/mTOR and ERK/MAPK signaling and 
are more likely to respond to tyrosine kinase inhibitors.13 
In contrast, VHL-deficient tumors expressing only HIF-2α 
display elevated c-Myc activity, driving proliferation in a 
growth factor-independent manner and resulting in enhanced 
proliferation and resistance to replication stress, and may 
therefore mark a subset of RCCs that are uniquely resistant 
to the current targeted drugs.13
In this study, we found that tumors with double c-Myc/
HIF-2α-positive staining were associated with a significantly 
lower PFS, which would be in consonance with that hypoth-
esis. In addition, a trend toward worse, but not significant 
clinical outcomes was found in those patients bearing tumors 
with positive staining to c-Myc.
Many clinical studies have correlated the presence of 
either HIF-α subunit with poor patient outcomes. However, 
each HIF-α may have the potential to be a tumor promoter 
or suppressor depending on the biology of a given type and 
its stage of development.14
Here, we also explored the correlation between HIF-α 
expression and sunitinib activity. In our study, 29% of the 
samples showed positive staining for HIF-1α or HIF-2α, 
although this was not associated with clinical response to 
sunitinib. This is in contrast to data from previous studies that 
are not published yet in which it was observed that HIF-α 
levels in tumors were strongly associated with sunitinib 
efficacy.30,31 These authors suggested that patients with tumors 
containing a high level of HIF-1α or HIF-2α were more likely 
to achieve a favorable sunitinib outcome. These findings are 
consistent with a recent study, where it was suggested that 
the immunoexpression of HIF-1α might support the predic-
tion of a good response to sunitinib treatment.6 In agreement, 
Garcia-Donas et al, in an observational and prospective 
study carried out in 101 ccRCC patients treated with first-
line sunitinib, observed that overexpression of HIF-2α was 
significantly associated with clinical benefit, longer OS and 
a tendency for longer PFS.32 Conversely, but in consonance 
with our results, Choueiri et al, in a study conducted in 65 
available tumor samples of patients who received pazopanib, 
did not find any association between the level of expression 
of HIF-1α or HIF-2α and clinical response to pazopanib.33 
As found in our study, treatment benefit differences probably 
cannot be explained on the basis of one marker only.
On the other hand, our findings, stemming from the usual 
clinical practice, showed an ORR of 41%, a CBR of 87% and 
a median PFS of 10.5 months with a safety profile as was 
expected. These data resemble those obtained in the Phase III 
pivotal clinical trial with sunitinib.22 The rate of CR with 
sunitinib in our population was greater than expected (7.4% 
in our study vs 3% in the Phase III clinical trial), and it could 
be associated with a good therapy management.
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Some limitations of this study have to be addressed. 
First, compared with data previously reported,13,31,33 there 
was a lower proportion of tissue tumor samples in which 
positive expression of the biomarkers analyzed was identi-
fied. These studies used different antibodies against HIF-1α 
and HIF-2α from our study. In addition, we should also bear 
in mind the variable quality of the tissue sections used for 
IHC analysis and the techniques used, such as IHC scoring, 
not employed in daily practice; thus, no consensus criteria 
for quantification are established yet. Another limitation 
is the small sample size; despite the fact that baseline 
characteristics were similar and balanced, the sample size 
for each tested biomarker was small, particularly for the 
HIF2-α/c-Myc-positive subset. In addition, it should be 
borne in mind that intratumor heterogeneity can lead to 
underestimation of the tumor genomics landscape portrayed 
from single tumor biopsy samples and may present major 
challenges to biomarker development.34 Finally, we used tis-
sue from the primary tumor; nowadays, it seems to be more 
important to analyze what is happening in the metastases 
rather than in the tumor, considering the neoplasms as a 
changing entity that can express different biomarkers over 
time, according to the information provided by the studies 
with modern immunotherapies.
In conclusion, these preliminary results suggest that pre-
dictive subgroups might be defined based on biomarkers such 
as c-Myc/HIF-2α. Further validation with a larger sample of 
patients is needed to confirm it.
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Figure 3 Kaplan–Meier estimates according to c-Myc.
Notes: (A) PFs according to c-Myc expression; (B) PFs according to c-Myc and MsKcc risk group; (C) PFs according to c-Myc and hiF-2α expression.
Abbreviations: hiF, hypoxia-inducible factor; MsKcc, Memorial sloan-Kettering cancer center; PFs, progression-free survival.
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